3 ms·

Presumably this would only be done for those found to be at risk based on tested testosterone levels. Fortunately the linked paper doesn't recommend it, only n

• sandworm101 6y ago
  That's the difference between treating patients and reducing spread. Appling a preventative to a small population of at-risk individuals will help them individually but won't decrease spread with the population, won't decrease their exposure. That requires preventing the infection from spreading amongst all people, including those who are at no real risk. This is one of those special situations where one contemplates a applying treatment to patients A B and C not to protect them from harm but to protect them from spreading something to patients D and E. The ethical difficulty is how one balances the potential increased in risks to ABC against the benifits to DE. What if hormone therapy to ABC reduces their lifespan? What it if causes long term behavioral or repoductive changes? How should that be balanced against D and E's chances of infection/death? Remember that any widespread COVID therapy will likely be with us as long as the disease. Altering hormone levels across a population, potentially for many years or even decades, is a radical approach. And to think of altering testosterone amongst the reproductive-aged population, potentially modifying sexual development of exposed children too, to safeguard those beyond reproductive age from COVID? That's a very dangrous area.